Omaxe Q2 FY27 Results: Board Meeting on October 27

Omaxe Limited’s board of directors is scheduled to meet on October 27, 2026, to consider and approve unaudited financial results for the July-September quarter of FY27. The agenda also covers the company’s half-year results for the period ended September 30, 2026. The real estate developer had not filed the Q2 figures at the time of the board-meeting intimation. The announcement is therefore a scheduled corporate action rather than a disclosure of quarterly performance. Investors will focus on whether the improvement reported in the June quarter continued through the September quarter.

Board meeting covers Q2 and half-year results

Omaxe informed the BSE on October 22 that its board would consider standalone and consolidated unaudited financial results. The meeting relates to Q2 FY27, which covers July through September 2026. It will also review the unaudited financial performance for the first half of FY27, ended September 30. The company’s previous quarterly results were considered by its board on August 12, 2026. Omaxe subsequently filed its unaudited June-quarter results on that date.

Q2 figures were not filed in the update

The available board-meeting notice does not contain revenue, profit, margin, sales, cash flow, debt, or project-level data for Q2 FY27. As a result, the September-quarter financial outcome cannot be assessed from the notice alone. The board’s consideration of the accounts does not by itself indicate whether revenue or profit rose or fell in the quarter. Any assessment of Q2 performance will need to wait for the formal financial-results filing. The distinction is important because the notice is procedural and does not change Omaxe’s stated operational or financial position.

June quarter marked a return to profit

Omaxe’s latest reported quarterly figures are for the quarter ended June 30, 2026, or Q1 FY27. The company reported revenue of ₹406 crore, compared with ₹282 crore in the year-earlier quarter. That represented year-on-year revenue growth of 43.9%. Net profit was ₹1.30 crore, compared with a net loss of ₹186 crore in the corresponding quarter a year earlier. Earnings per share for the June 2026 quarter were ₹0.05.

Sequential revenue movement was also positive

The June-quarter revenue of ₹406 crore was also reported as 16.5% higher than the preceding quarter. Omaxe’s operating profit margin for Q1 FY27 was stated at 1.8%. The return to a positive net result followed a loss in the corresponding June 2025 quarter. However, the reported profit of ₹1.30 crore was modest relative to quarterly revenue, making margins and the quality of subsequent earnings relevant for investors. The forthcoming Q2 filing will provide the next official financial comparison.

Key reported figures at a glance

All absolute revenue figures in the table are presented in ₹ crore. The data reflects the latest reported quarter cited in the company-related disclosures. It does not represent Q2 FY27 results. Omaxe’s formal September-quarter statement may include updated standalone and consolidated data, along with half-year comparatives. Until that filing is made, the June quarter remains the latest available performance reference.

Trading window remains closed through October 29

Omaxe said its trading window for dealing in the company’s equity shares would remain closed from October 1 through October 29, 2026. The closure was described as being in line with SEBI LODR-related insider-trading compliance requirements. Such windows restrict designated persons from trading while unpublished price-sensitive information, including financial results, is being handled. The stated window extends beyond the October 27 board meeting date. This filing is a compliance measure and does not provide an indication of the forthcoming results.

Capital returns remain a relevant financial measure

The available data showed Omaxe’s 12-month return on invested capital, or ROIC, at negative 24.8% in Q1 FY27. The stated cost of capital was 12%. ROCE was not shown in the available quarterly snapshot. These metrics provide context beyond revenue and net profit because they relate to returns generated from the capital deployed in the business. The Q2 and half-year results may offer updated figures or further detail on the company’s financial position.

What investors may watch in the filing

The formal Q2 disclosure will be important for confirming revenue and profitability for the July-September period. Market participants can compare any reported revenue with the ₹406 crore posted in Q1 FY27 and the ₹282 crore recorded in the year-earlier June quarter. They can also assess whether Omaxe maintained a positive net result after the ₹1.30 crore profit in June. Consolidated and standalone figures may differ, so both sets of financial statements will be relevant. The half-year statement should provide a broader view of performance through September 30.

Next official update is the results announcement

Omaxe’s October 27 board meeting is scheduled to consider the Q2 FY27 and first-half FY27 unaudited financial results. The company has not disclosed the September-quarter figures in the board-meeting intimation. Its latest reported quarter showed 43.9% year-on-year revenue growth and a return to profit. The next confirmed step is the release of the board-approved financial results following the meeting. The trading window is scheduled to remain closed until October 29, 2026.